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The endocannabinoid system plays a critical role in
the control of energy homeostasis, but the identity
and localization of the endocannabinoid signal
involved remain unknown. In the present study, we
developed transgenic mice that overexpress in
forebrain neurons the presynaptic hydrolase, mono-
acylglycerol lipase (MGL), which deactivates the en-
docannabinoid 2-arachidonoyl-sn-glycerol (2-AG).
MGL-overexpressing mice show a 50% decrease in
forebrain 2-AG levels but no overt compensation in
other endocannabinoid components. This biochem-
ical abnormality is accompanied by a series of meta-
bolic changes that include leanness, elevated energy
cost of activity, and hypersensitivity to b3-adren-
ergic-stimulated thermogenesis, which is corrected
by reinstating 2-AG activity at CB1-cannabinoid
receptors. Additionally, themutant mice are resistant
to diet-induced obesity and express high levels of
thermogenic proteins, such as uncoupling protein
1, in their brown adipose tissue. The results suggest
that 2-AG signaling through CB1 regulates the
activity of forebrain neural circuits involved in the
control of energy dissipation.
INTRODUCTION
Endocannabinoid signaling at CB1 receptors plays a critical role
in energy homeostasis (for review, see Mackie, 2006; Matias and
Di Marzo, 2007). Preclinical and clinical studies have shown that
CB1 activation stimulates food intake (Kirkham, 2009), increases
lipogenesis in white adipose tissue and liver (Cota et al., 2003;CeOsei-Hyiaman et al., 2005; Herling et al., 2008), and promotes
insulin resistance in skeletal muscle (Eckardt et al., 2009).
Conversely, pharmacological blockade or genetic ablation of
CB1 receptors decreases food intake, accelerates energy
expenditure, and corrects metabolic abnormalities associated
with obesity in rodents (Matias and Di Marzo, 2007; Bajzer
et al., 2011). Consistent with those data, clinical trials have
shown that CB1 inverse agonists are effective in lowering body
weight and attenuating metabolic syndrome in obese human
subjects (Ioannides-Demos et al., 2011).
While the studies outlined above underscore the importance
of CB1 receptors in metabolic control, they provide no informa-
tion about the identity or localization of the endocannabinoid
signals involved. Three lines of evidence point to a peripheral
site of regulation (Kunos and Tam, 2011). First, feeding status
and obesity regulate the production of two endocannabinoid
mediators—2-arachidonoyl-sn-glycerol (2-AG) and ananda-
mide—in peripheral tissues (Go´mez et al., 2002; Engeli et al.,
2005; Osei-Hyiaman et al., 2005). Second, CB1 antagonists
with restricted access to the brain retain the ability to reduce
body weight gain and improve metabolic parameters in mouse
models of obesity (LoVerme et al., 2009; Tam et al., 2010). Lastly,
mutant mice that do not express CB1 receptors in adipocytes
display a lean phenotype (Mancini et al., 2010), while mice lack-
ing CB1 in hepatocytes are protected against diet-induced
insulin resistance (Osei-Hyiaman et al., 2008).
Other evidence indicates, however, that endocannabinoid
signaling in the central nervous system (CNS) also contributes
to energy homeostasis (Matias and Di Marzo, 2007). In addition
to modulating the hedonic properties of food, which can directly
influence energy intake (Kirkham, 2009), CB1 receptors in the
brain may also control energy expenditure (Matias and Di Marzo,
2007). In the paraventricular nucleus of the hypothalamus, for
example, CB1 colocalizes with cocaine- and amphetamine-
regulated transcript (CART) (Cota et al., 2003), a neuropeptide
that regulates sympathetic activity and brown adipose tissuell Metabolism 15, 299–310, March 7, 2012 ª2012 Elsevier Inc. 299
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Brain 2-AG Signaling Controls Energy Metabolism(BAT) thermogenesis (Elmquist, 2001; Abbott et al., 2001; Kong
et al., 2003; Hentges et al., 2005; Tung et al., 2007; Smith
et al., 2008). Confirming the functional significance of this local-
ization, CB1 deletion in mouse forebrain neurons causes a series
of phenotypic changes that include leanness, resistance to diet-
induced obesity, and increased heat production (Quarta et al.,
2010). A role for central endocannabinoid signaling in energy
homeostasis is further supported by the finding that leptin, an
adipose-derived hormone that promotes energy utilization,
inhibits endocannabinoid production in the rodent hypothalamus
(Di Marzo et al., 2001), whereas the gastric hormone ghrelin,
which promotes energy intake, exerts an opposite effect (Kola
et al., 2008).
In the CNS, 2-AG is released by the action of two enzymes
found in dendritic spine membranes: phospholipase C-b
(PLC-b) and diacylglycerol lipase-a (DGL-a) (Stella et al., 1997;
Hashimotodani et al., 2005; Tanimura et al., 2010). PLC-b hydro-
lyses phosphatidylinositol 4-5 bisphosphate to generate 1,2-
diacylglycerol, which is cleaved by DGL-a to produce 2-AG
(Stella et al., 1997). 2-AG travels across the synapse and inhibits
neurotransmitter release by activating CB1 receptors on axon
terminals (Piomelli et al., 2007). This retrograde signaling
process is interrupted by either of two intracellular 2-AG-degrad-
ing enzymes—monoacylglycerol lipase (MGL), which is localized
to presynaptic terminals (Dinh et al., 2002; Gulyas et al., 2004),
or a-b-hydrolase domain 6 (ABHD6), which is found in postsyn-
aptic spines (Blankman et al., 2007; Marrs et al., 2010). As
expected from the known functions of these enzymes, genetic
deletion of DGL-a decreases, while deletion of MGL increases
2-AG content in the mouse brain (Tanimura et al., 2010; Gao
et al., 2010; Chanda et al., 2010; Schlosburg et al., 2010). Abla-
tion of DGL-a or MGL also causes, however, substantial
changes in the steady-state levels of anandamide and arachi-
donic acid (AA) (Gao et al., 2010; Chanda et al., 2010; Schlosburg
et al., 2010), which limits the usefulness of DGL-a and MGL null
mice as models to define the central functions of 2-AG. In the
present study, we generated transgenic mice that selectively
overexpress MGL in forebrain neurons. Compared to their
wild-type littermates, these mutants show a 50% reduction in
forebrain 2-AG levels but no overt compensation in other
components of the endocannabinoid system. Their metabolic
phenotype suggests that 2-AG signaling through CB1 regulates
the activity of forebrain neural circuits that control energy
expenditure.
RESULTS
Generation of MGL-Tg Mice
We created transgenic mouse lines that overexpress MGL in the
forebrain under the control of the CaMKIIa promoter (MGL-Tg
mice; Figure 1A). The transgene-encoded MGL was fused with
a V5 tag, which did not affect enzyme activity (see Figure S1A
available online). Founders were generated by pronuclear injec-
tion and mutants identified by genetic screening (Figure S1B).
MGL-Tg mice were viable and healthy, and displayed normal
responses to a standard set of neuromuscular tests (Crawley,
2000). The CaMKIIa-MGL transgene produced robust MGL
expression throughout the adult forebrain (Figures 1B and 1C),
with a distribution pattern resembling that of CaMKIIa (Mayford300 Cell Metabolism 15, 299–310, March 7, 2012 ª2012 Elsevier Inc.et al., 1995; Casanova et al., 2001). Particularly high expression
was noted in cortex and hippocampus, but significant levels
were also seen in other regions (Figures 1B and 1C). Immunohis-
tochemical analyses confirmed this distribution (Figure 2).
MGL-TgMice Have a Selective Deficit in Forebrain 2-AG
Consistent with protein expression, MGL activity was higher and
2-AG levels were lower in the forebrain of MGL-Tg mice, relative
to wild-type controls (Figures 1D and 1E). Additional lipid anal-
yses revealed that MGL overexpression preferentially altered
2-AG content, producing only a modest decrease in other
2-acyl-sn-glycerols (Table S1) and without altering anandamide,
AA (Figure 1F), or other free fatty acids (Table S1). Moreover,
there were no detectable changes in the transcription of various
endocannabinoid-related genes (Figure 1G and Figure S1C).
MGL expression was unchanged in peripheral tissues of MGL-
Tg mice, including sympathetic stellate ganglia (Figure 1H),
and normal MGL activity was found in spleen and BAT, which
are densely innervated by sympathetic fibers (Figures S2A and
S2B). No alterations in 2-AG or AA were observed in a panel of
peripheral tissues that included BAT, spleen, and liver (Figures
S2C and S2D). The results suggest that CaMKIIa-driven MGL
overexpression accelerates 2-AG degradation and reduces
2-AG availability. Importantly, this effect is restricted to the fore-
brain and is not associated with overt changes in other compo-
nents of the endocannabinoid system.
MGL-Tg Mice Are Lean, Hyperphagic, and Hypoactive
Starting from 14 weeks of age, the body-weight trajectory of
MGL-Tg mice diverged from that of their wild-type littermates.
Transgenic animals showed reduced weight gain (Figure 3A),
decreased adiposity (Figure 3B), and increased lean mass (Fig-
ure 3C) relative to controls. These differences in body composi-
tion were accompanied by lower plasma triglyceride levels
(Figure 3D), decreased serum glucose levels (Figure 3E), and
heightened glucose uptake (Figure 3F). By contrast, total body
water (Figure 3G) and dietary fat absorption (Figure S3A) were
identical in the two strains. Despite their reduced body weight,
MGL-Tg mice fed more frequently (Figure 3H and Figures
S3B–S3D), ate a greater amount of food (Figure 3I), and moved
less (Figure 3J) than did control mice. This unusual coexistence
of leanness, increased feeding, and reduced motor activity was
the most prominent outward feature of MGL-Tg mutants.
MGL-Tg Mice Are Resistant to Diet-Induced Obesity
To investigate this feature further, we exposed the mice to
a high-fat diet (60 kcal % fat) for 10 weeks. Although wild-type
andMGL-Tg mice consumed equal amounts of food (Figure S4),
the former became obese, whereas the latter gained only
a modest amount of weight (Figures 4A–4C), displaying mark-
edly reduced feed efficiency (Figure 4D) and fat mass (Figure 4E
and Table S2). In addition, MGL-Tg mice did not present any of
the metabolic signs that typically accompany obesity, showing
no evidence of liver steatosis (Figures 4F and 4G), insulin resis-
tance (Figure 4H), or leptin resistance (Figure 4I). As seen with
mice kept on standard chow, blood glucose and triglyceride
levels in fat-fed transgenic mice were significantly lower than
those found in controls (Figures 4J and 4K). A plausible interpre-
tation of these results is that lowered forebrain 2-AG availability
Figure 1. Biochemical Characterization of MGL-Tg Mice
(A) Schematic representation of the pMM403-CamKIIa-MGL-V5 construct utilized to generate MGL-Tg mice. The arrows indicate the position of the amplicon
used for genotyping.
(B) MGL mRNA levels in brain regions of wild-type mice (open bars) or MGL-Tg mice (closed bars). PFC, prefrontal cortex; Cx, rest of the cortex; Hipp,
hippocampus; Str, striatum; Hypo, hypothalamus; Thal, thalamus; Cere, cerebellum. Results are expressed as mean ± SEM. **p < 0.01 and ***p < 0.001 (n = 3).
(C) MGL protein levels in brain regions of wild-type (Wt) or MGL-Tg mice. Arrows indicate the apparent molecular weight (MW, in kDa) of the MGL-V5 transgene,
endogenous MGL, and actin (used as standard). The experiment was repeated twice with identical results.
(D and E) (D) MGL activity and (E) 2-AG levels in various brain regions of wild-type (open bars) or MGL-Tg mice (closed bars).
(F) Anandamide (AEA) and arachidonic acid (AA) levels in the cortex. **p < 0.01 and ***p < 0.001 (n = 6–7).
(G) Levels of mRNAs encoding for CB1 (CB1R), diacylglycerol lipase-a (DGL-a), a-b-hydrolase domain 6 (ABHD6), N-acylphosphatidylethanolamine-specific
phospholipase D (NAPE-PLD), and fatty acid amide hydrolase-1 (FAAH-1) in the forebrain of wild-type (open bars) or MGL-Tg mice (closed bars) (n = 5).
(H) MGL mRNA levels in various tissues of wild-type (open bars) or MGL-Tg mice (closed bars). Abbreviations: BAT, brown adipose tissue; WAT, white adipose
tissue; LV, liver; GNG, sympathetic stellate ganglion. ***p < 0.001 (n = 3). The inset shows liver and GNG data in a magnified scale.
Results are expressed as mean ± SEM.
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Figure 2. Neuroanatomical Characterization of
MGL-Tg Mice
(A) Immunohistochemical localization of MGL in coronal
brain sections from wild-type (Wt) and MGL-Tg (Tg) mice,
using an antibody that recognizes both native and trans-
gene-encoded MGL. The insets show nuclear staining
with 40,6-diamidino-2-phenylindole (DAPI). The dashed
boxes marked b, d, and e highlight sections that are
magnified in (B)–(E).
(B and C) Immunohistochemical localization of MGL in
hippocampus of MGL-Tg mice. A laminar, punctuated
immunostaining pattern (green) is observed in the stratum
oriens (o), stratum radiatum (r), hilus (h), and stratum mo-
leculare (m) of the dentate gyrus. Other abbreviations: p,
stratum pyramidale; lm, stratum lacunosum-moleculare;
g, stratum granulosum. DAPI staining is shown in blue.
(D and E) Immunohistochemical localization of MGL in the
paraventricular (PVN, D) and arcuate nuclei (ARC, E) of the
hypothalamus in wild-type (Wt) and MGL-Tg (Tg) mice
(dashed boxes d and e in A). The insets in (D) and (E) show
negative control staining of adjacent slides using antibody
preabsorbed with purified MGL (0.18 mg/ml).
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ders MGL-Tgmice resistant to obesity andmetabolic syndrome.
MGL-Tg Mice Show High Energy Cost of Activity
Indirect calorimetry measurements showed no difference in
average energy expenditure, respiratory quotient, or oxygen
consumption between MGL-Tg and wild-type mice (Figures
S5A and S5B). A regression analysis of the calorimetry data
revealed, however, that transgenic mice used a greater amount
of energy for any given level of motor activity (Figures 5A and
5B). Additional tests showed that core body temperature (Fig-
ure 5C) and, particularly, thermogenic responses to pharmaco-
logical activation of b3-adrenergic receptors (Figure 5D) were
higher in transgenic mice than controls. Consistently, b3-adren-
ergic receptor expression (Figure 5E) and mitochondrial
complex I and III activity (Figure 5F) were elevated in BAT from
MGL-Tg mice. These traits are consistent with a heightened
energetic cost of motor activity resulting, at least in part, from
enhanced thermogenesis.302 Cell Metabolism 15, 299–310, March 7, 2012 ª2012 Elsevier Inc.Impaired 2-AG Signaling at CB1
Receptors Underlies Enhanced
Thermogenesis
To determine whether deficits in 2-AG signaling
at CB1 account for the abnormal thermoregula-
tion observed in MGL-Tg mice, we treated the
animals with a single dose of the irreversible
MGL inhibitor JZL184 (Long et al., 2009a) and
measured baseline and b3-adrenergic-induced
thermogenesis 6 hr later. As expected (Long
et al., 2009b), JZL184 inhibited brain MGL
activity (Figure S6A) and increased brain 2-AG
levels (Figure S6B), without affecting DGL
activity (Figure S6C). Moreover, JZL184 caused
a modest hypothermia in both strains (Fig-
ure S6D). However, the most notable conse-
quence of MGL blockade was a normalizationof the thermogenic response to b3-receptor activation in trans-
genic mice (Figure 5D). This effect was reversed by the CB1
inverse agonist rimonabant, providing evidence that it resulted
from restoration of 2-AG signaling at CB1 (Figure 5D). Further-
more, rimonabant enhanced b3-adrenergic-induced hyper-
thermia in wild-type mice (Figure 5D), which is suggestive of an
intrinsic endocannabinoid modulation of thermogenesis (Long
et al., 2009b). JZL184 did not normalize other phenotypic
changes observed in MGL-Tg mice, including plasma levels of
glucose, insulin and leptin, or body weight (Figures S6E and
S6F). Collectively, the results suggest that 2-AG signaling at
CB1 regulates the activity of forebrain circuits that control energy
dissipation.
Increased Mitochondrial Density in BAT
We next asked whether alterations in the morphology of BAT
mitochondria may account for the increased thermogenic
response observed in MGL-Tg mice. Electron microscopy
studies showed that the mitochondrial to cytoplasmic area ratio
Figure 3. MGL-Tg Mice Are Lean, Hyper-
phagic, and Hypoactive
(A) Body-weight trajectory in wild-type (squares)
and MGL-Tg mice (triangles) kept on a standard
diet. *p < 0.05 and ***p < 0.001 (n = 10).
(B and C) Body adiposity (B) and lean mass (C)
in 20-week-old wild-type (Wt, open bars) and
MGL-Tg mice (closed bars), as assessed by
magnetic resonance imaging. *p < 0.05 and **p <
0.01 (n = 8).
(D) Plasma triglycerides levels (mg/dl) in free-
feeding (FF) or 4 hr food-deprived (FD) wild-type
(open bars) and MGL-Tg mice (closed bars). *p <
0.05 and ***p < 0.001 (n = 3).
(E) Serum glucose levels (mg/dl) in 4 hr food-
deprived wild-type (open bars) and MGL-Tg mice
(closed bars). *p < 0.05 (n = 5).
(F) Time course (min) of glucose uptake (mg/dl) in
wild-type (squares) and MGL-Tg mice (triangles).
*p < 0.05 and ***p < 0.001 (n = 5).
(G) Water body content (percent body mass) of
20-week-old wild-type (Wt, open bars) and
MGL-Tg mice (closed bars), as assessed by MRI
(n = 8).
(H) Meal frequency (number of meals/hr) in adult
wild-type (Wt, open bars) and MGL-Tg mice
(closed bars). ***p < 0.001 (n = 10).
(I) Time course (hr) of daily food intake in adult wild-
type (squares) and MGL-Tg mice (triangles). *p <
0.05 and ***p < 0.001 (n = 10).
(J) Time course (hr) of daily motor activity (cumu-
lative counts) in adult wild-type (squares) and
MGL-Tg mice (triangles). **p < 0.01 and ***p <
0.001 (n = 10 each).
Results are expressed as mean ± SEM.
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6A and 6B). This difference was likely due to changes in mito-
chondrial area and density (Figures S7A and S7B). Additional
investigations showed that uncoupling protein 1 (UCP1) (Figures
6C and 6D) and type 2 iodothyronine deiodinase (Figure S7C)
were elevated in BAT of transgenic mice, confirming the pres-
ence of a heightened thermogenic capacity in these mutants.
Changes in CART Expression in Hypothalamus
To identify neural circuits that might bemodified byMGL overex-
pression, we surveyed the hypothalamus of transgenic mice for
quantitative changes in a set of 42 mRNAs encoding for proteins
known to participate in systemic metabolism. Among the tran-
scripts targeted by our analysis (Table S3), only that encoding
for the neuropeptide CART showed statistically detectable
elevations in MGL-Tg mice (Table S4). There was a trend to
higher Pomc mRNA content, but this failed to reach statistical
significance (p = 0.063; Table S4). By contrast, the transcription
of other genes involved in energy homeostasis—including leptin
receptor and agouti-related peptide—was similar between
transgenic and control animals (Table S4). Quantitative RT-PCR
and western blot analyses confirmed that CART expression was
markedly elevated in the hypothalamus, but not in several otherCebrain regions of MGL-Tg mice (Figures 7A and 7B). In agreement
with the known localization of CART-expressing neurons (Gaut-
vik et al., 1996; Fekete and Lechan, 2006), in situ hybridization
and immunohistochemistry experiments identified the arcuate
nucleus and dorsomedial hypothalamus as sites of enhanced
CART mRNA transcription (Figure 7C), and the paraventricular
nucleus as a site of increased CART peptide localization (Fig-
ure 7D). These findings suggest that CART expression is
increased in MGL-Tg mice.
DISCUSSION
The present report describes the phenotype of transgenic mice
that overexpressMGL in forebrain neurons. Themutation causes
a widespread reduction in forebrain 2-AG levels along with
a series of behavioral and metabolic traits that are suggestive
of excessive heat production. Compared to their wild-type
littermates, MGL-Tg mice are lean, hyperphagic, resistant to
diet-induced obesity, hyperthermic, and hypersensitive to
b3-adrenergic-stimulated thermogenesis. The latter abnormality
is corrected by pharmacological blockade of MGL activity,
which restores the ability of endogenous 2-AG to engage CB1
receptors. Collectively, the results indicate that central 2-AGll Metabolism 15, 299–310, March 7, 2012 ª2012 Elsevier Inc. 303
Figure 4. MGL-Tg Mice Are Resistant to High-Fat Diet-Induced Obesity
(A) Representative images of wild-type (Wt) and MGL-Tg mice (Tg) after 10 weeks of high-fat diet.
(B) Body-weight trajectories (g) in wild-type mice (squares) and MGL-Tg mice (triangles) maintained on a high-fat diet. *p < 0.05 and ***p < 0.001 (n = 5–6).
(C–E) Body weight gain (percent initial body weight) (C), feed efficiency (g body weight/g food intake) (D), and fat mass (percent body weight) (E) in wild-type (open
bars) and MGL-Tg mice (closed bars) kept on a high-fat diet. ***p < 0.001 (n = 5–6).
(F) Triglyceride levels (mg/mg fresh tissue weight) in liver tissue from wild-type (open bars) and MGL-Tg mice (closed bars) kept on a high-fat diet. ***p < 0.001
(n = 5–6).
(G) Neutral lipids staining (oil red O) in sections of liver tissue from wild-type (Wt) and MGL-Tg mice (Tg) kept on a high-fat diet. Magnification: top, 103;
bottom, 403.
(H and I) Plasma levels of insulin (H) and leptin (I) in wild-type (open bars) andMGL-Tgmice (closed bars) kept on normal (ND, n = 3) or high-fat diet (HFD, n = 5–6).
*p < 0.05 and ***p < 0.001.
(J and K) Plasma levels of glucose (J) and triglycerides (K) in wild-type (open bars) and MGL-Tg mice (closed bars) kept on a high-fat diet. **p < 0.01 and
***p < 0.001 (n = 5–6).
Results are expressed as mean ± SEM.
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Figure 5. MGL-Tg Mice Have High Energy Cost of Activity and Are Hypersensitive by b3-Adrenergic Thermogenesis
(A) Regression analysis of energy expenditure (kcal/hr/kg body weight) andmotor activity (beam breaks) in wild-type (green circles) andMGL-Tgmice (red circles)
kept on a normal diet.
(B) Energy cost of motor activity (slope of regression curve in A) in wild-type (Wt, open bars) and MGL-Tg mice (Tg, closed bars). **p < 0.01 (n = 8).
(C) Average body temperature in wild-type (Wt, open bars) and MGL-Tg mice (Tg, closed bars). *p < 0.05 (n = 8).
(D) Time course (min) of body temperature changes elicited by b3-adrenergic agonist CL-316243 (0.1 mg/kg) in wild-type (squares) and MGL-Tg mice (triangles).
CL-316243 was administered alone (left panel), together with MGL inhibitor JZL184 (16 mg/kg, 6 hr before CL-316243) (center panel), or together with JZL184
plus CB1 inverse agonist rimonabant (10 mg/kg) (right panel). *p < 0.05, **p < 0.01, and ***p < 0.001 (n = 5–7).
(E) Levels of mRNA encoding for b3-adrenergic receptor in BAT from wild-type (Wt, open bars) and MGL-Tg mice (Tg, closed bars) fed with normal chow.
**p < 0.01 (n = 3).
(F) Mitochondial complex activity (I + III) in BAT isolated from wild-type (Wt, open bars) and MGL-Tg mice (Tg, closed bars). *p < 0.05, **p < 0.01, and ***p < 0.001
(n = 3–4).
Results are expressed as mean ± SEM.
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dissipation.
2-AG is considered the main endocannabinoid mediator of
retrograde signaling at CNS synapses (Katona and Freund,Ce2008). Experiments in brain slices have suggested that activation
of postsynaptic DGL-a releases 2-AG (Jung et al., 2005), which
then diffuses across the synapse to bind CB1 receptors on
axon terminals (Katona and Freund, 2008). These experimentsll Metabolism 15, 299–310, March 7, 2012 ª2012 Elsevier Inc. 305
Figure 6. Increased Mitochondria Density in BAT
of MGL-Tg Mice
(A) Representative electron microscopy images of BAT
from wild-type (Wt) and MGL-Tg mice (Tg). L, lipid
vacuole; N, cell nucleus.
(B) Ratio of mitochondria area to cytosol area in BAT from
wild-type (Wt, open bars) and MGL-Tg mice (Tg, closed
bars) fed with normal chow. *p < 0.05 (n = 3–4).
(C and D) Levels of uncoupling protein 1 (UCP1) assessed
by western blot analysis (C) or immunohistochemistry (D)
in BAT from wild-type (Wt, open bars) and MGL-Tg mice
(Tg, closed bars) fed with normal chow. Protein levels were
quantified using the NIH ImageJ software and actin as
a standard. **p < 0.01 (n = 4).
Results are expressed as mean ± SEM.
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genetic models have been developed to fill this knowledge gap.
Deletion of DGL-a lowers brain 2-AG levels and suppresses en-
docannabinoid signaling in the mouse hippocampus (Tanimura
et al., 2010; Gao et al., 2010), but also alters the steady-state
levels of two endocannabinoid-related lipids: anandamide and
AA (Gao et al., 2010). On the other hand, MGL deletion causes
2-AG to accumulate in the mouse brain, which results in CB1
receptor desensitization and tolerance to the effects of cannabi-
noid agonists (Chanda et al., 2010; Schlosburg et al., 2010).
Because of these compensatory events, DGL-a- and MGL null
mice do not provide definitive insights on the roles played by
2-AG in vivo. Pharmacological approaches aimed at inhibiting
DGL-a or MGL also suffer from various limitations, including
inadequate target selectivity (Hoover et al., 2008) and dose-
dependent CB1 receptor desensitization (Schlosburg et al.,
2010; Busquets-Garcia et al., 2011; Sciolino et al., 2011). Here,
we utilized the CaMKIIa promoter to drive MGL expression in
forebrain neurons (Mayford et al., 1995, 1997). This allowed us
to generate mice in which MGL activity is enhanced in the fore-
brain, but not cerebellum, sympathetic ganglia, or peripheral
organs. Importantly, the resulting decrement in 2-AG availability
does not trigger compensatory mechanisms such as those
observed in mice that do not express DGL-a or MGL (Chanda
et al., 2010; Schlosburg et al., 2010). The reasons for this
apparent lack of compensation are unclear, but might relate to
the late developmental activation of the CaMKIIa promoter
(Kojima et al., 1997; Mayford et al., 1997) or the presence of
residual 2-AG levels in MGL-Tg mice. Thus, the first main result
of our study is the generation of an animalmodel inwhich a selec-
tive deficiency in central 2-AG signaling can be unequivocally
linked to alterations in phenotype.
We identified four sets of phenotypic changes that differen-
tiate MGL-Tg mice from their wild-type littermates. First, MGL-
Tg mice eat more and move less than do control animals.
Second, irrespective of whether they are fed a normal or high-306 Cell Metabolism 15, 299–310, March 7, 2012 ª2012 Elsevier Inc.fat diet, MGL-Tg mice are resistant to body-
weight gain, and their blood glucose and triglyc-
eride levels are lower than those of wild-type
controls. Third, MGL-Tg mice are strikingly
hypersensitive to the thermogenic effects of
b3-adrenergic activation. Fourth, the BAT ofMGL-Tg mice displays higher mitochondrial density and expres-
sion of proteins involved of nonshivering thermogenesis (Silva,
2006). Additionally, experiments with the MGL inhibitor JZL184
(Long et al., 2009a) showed that reinstating intrinsic 2-AG activity
at CB1 receptors normalizes b3-adrenergic-dependent thermo-
genesis in MGL-Tg mice. These findings provide evidence that
forebrain 2-AG signaling through CB1 helps conserve body
energy by quenching heat production. Supporting an energy-
sparing role for central 2-AG, conditional mutant mice that lack
CB1 receptors in the forebrain and express fewer CB1 receptors
in sympathetic neurons were also shown to be hyperthermic,
lean, and resistant to diet-induced obesity (Quarta et al., 2010).
As 2-AG is a mediator of retrograde synaptic transmission
throughout the CNS (Katona and Freund, 2008), it is likely that
2-AG signaling at more than one forebrain site contributes to
metabolic control. This is an important area for future
investigation.
In conclusion, the present report introduces MGL-Tg mice as
a new model to investigate the functions of central 2-AG-medi-
ated endocannabinoid signaling. The phenotypic changes dis-
played by these mice suggest that 2-AG acting at brain CB1
receptors may help to conserve body energy by moderating
heat dissipation. These effects appear to be synergic with those
exerted by CB1 receptors in peripheral tissues (Kunos and Tam,
2011), further underscoring the pervasive roles of endocannabi-
noid signaling in energy metabolism.
EXPERIMENTAL PROCEDURES
Transgene Construction
We constructed the MGL transgene expression vector by inserting a 1.0 kb rat
MGL-V5 polymerase chain reaction (PCR) product into the BamHI site of
pNN265. The 2.5 kb NotI fragment of the plasmid, which encodes Mgll-V5,
50- and 30-intron, and poly(A) signal from SV40 (Choi et al., 1991), was then
inserted into the pMM403 vector containing a 8.5 kb CaMKIIa promoter
sequence (Mayford et al., 1995) to generate the pMM403-MGL construct,
the identity of which was verified by DNA sequencing. MGL expression and
Figure 7. CART Overexpression in the Hypothal-
amus of MGL-Tg Mice Fed with Normal Chow
(A) CARTmRNA levels in various brain regions of wild-type
(Wt, open bars) and MGL-Tg mice (Tg, closed bars).
***p < 0.001 (n = 5–6).
(B) Western blot analyses of CART in the hypothalamus of
wild-type (Wt) and MGL-Tg (Tg) mice. The arrow indicates
the apparent molecular weight of synthetic CART
(55–102), which is shown in the blot on the right (Std). Note
that synthetic CART migrates as a monomer, dimer, or
trimer (6, 12, and 18 kDa, respectively). Results are from
one experiment replicated four times with similar results.
(C) Localization of CART mRNA in the hypothalamus of
wild-type (Wt) andMGL-Tg (Tg) mice. Abbreviations: ARC,
arcuate nucleus; DMH, dorsomedial hypothalamus.
(D) Immunohistochemical localization of CART peptide in
the hypothalamus of wild-type (Wt) andMGL-Tg (Tg) mice.
Abbreviation: PVN, paraventricular nucleus.
Results are expressed as mean ± SEM.
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(CHO) cells with pNN265-MGL (Figure S1A).
Transgenic Mice
We prepared an 11 kb linearized DNA containing the CaMKIIa promoter and
the Mgll transgene by digestion of pMM403-MGL with SfiI. Transgenic
founders were generated by pronuclear injection of linearized DNA into
C57BL6/J zygotes (Transgenic Mouse Facility, University of California, Irvine),
and male chimeras were crossed with C57BL6/J females. Animals were kept
at 22C on a 12 hr light/dark cycle, with free access to water and chow (Prolab
RMH 2500; PMI Nutrition International, Brentwood, MO). We used male mice
aged between 17 and 30 weeks under normal chow feeding, unless indicated
otherwise. All procedures met the National Institutes of Health Guidelines for
the Care andUse of Laboratory Animals andwere approved by the Institutional
Animal Care and Use Committee of the University of California, Irvine.
Quantitative PCR
We performed quantitative real-time PCR as detailed elsewhere (Jung et al.,
2011). Primers and fluorogenic probes were synthesized by TIB Molbiol (Adel-
phia, NJ, USA) or purchased from Applied Biosystems (TaqMan[R] Gene
Expression Assays, Foster City, CA, USA) (Table S5).
Protein Measurements
Western blot analyses were conducted as described (Jung et al., 2011).
Lipid Analyses
Lipid extraction and analysis by liquid chromatography/mass spectrometry
were conducted as described (Astarita and Piomelli, 2009).
MGL Activity Assays
Enzyme assays were conducted as described (Jung et al., 2011).
Immunohistochemistry
We perfused mice through their left heart ventricle with isotonic saline, and
then with a solution containing 4% paraformaldehyde in 0.1 M phosphate
buffer (PB, pH 7.2). Brains were collected, postfixed for 1 day in the fixation
solution, and cut in coronal sections with a cryostat (20 mm thickness). TheCell Metabolism 15,sections were treated with 0.3% hydrogen peroxide for
20 min and exposed to 3% normal goat serum for 1 hr at
room temperature. Sections were incubated overnight at
4C with an MGL antibody (1:500, Dinh et al., 2002) or
a CART antibody (1:1000, Phoenix Pharmaceuticals,
Burlingame, CA, USA), rinsed in 0.1 M PB, and exposed
to anti-mouse IgG conjugated with Alexa Fluor 488
(1:1000, Invitrogen, Carlsbad, CA, USA) for 1 hr.40-6-diamidino-2-phenylindole (DAPI)-containing medium (Vector Laborato-
ries, Burlingame, CA, USA) was used for nucleus staining. For 3,30-diamino-
benzidine (DAB) staining, the sections were washed after primary antibody in-
cubation and exposed to biotinylated goat anti-rabbit IgG (1:500, Vector
Laboratories) for 1 hr. After a 10 min rinse with 0.1 M PB, sections were
treated with avidin-biotin-peroxidase complex (ABC, 1:200, Vector Laborato-
ries) and developed with DAB with metal enhancer (Sigma-Aldrich, St. Louis,
MO, USA). Slides were rinsed, dehydrated in ascending ethanol concentra-
tions, cleared in xylene, and mounted with Eukitt mounting medium (Sigma-
Aldrich). Images were captured using an Eclipse E600 microscope (Nikon,
Tokyo, Japan).
Morphometric Analyses
Light Microscopy and Immunohistochemistry
BAT pieces were fixed overnight at 4C in 4% paraformaldehyde in 0.1 M
PB at pH 7.4. They were dehydrated, cleared, and paraffin embedded.
Sections from three different levels (100 mm apart) were stained with
hematoxylin and eosin for immunohistochemistry. UCP1 immunoreactivity
was examined as follows. For each section level, 3 mm thick dewaxed
sections were incubated with sheep anti-UCP1 (1:6,000, kindly provided
by Daniel Ricquier, Universite´ Paris Descartes, France) according to the
avidin-biotin complex (ABC) method, as follows: (1) endogenous peroxi-
dase blocking with 3% hydrogen peroxide in methanol; (2) normal rabbit
serum (1:75) for 20 min to reduce nonspecific background; (3) incubation
with primary antibodies against UCP1 overnight at 4C; (4) rabbit anti-
sheep IgG biotin conjugated (1:200; Vector Laboratories); (5) ABC kit
(Vector Labs); (6) enzymatic reaction to reveal peroxidase with Sigma
Fast 3,30-diaminobenzidine (Sigma-Aldrich) as substrate. Finally, sections
were counterstained with hematoxilin and mounted in Eukitt (Fluka, Dei-
senhofen, Germany). Images were captured with a Nikon Eclipse 80i light
microscope (Nikon).
Electron Microscopy
Immediately after removal, small tissue fragments were fixed in 2% glutaralde-
hyde-2% paraformaldehyde in 0.1 M PB (pH 7.4) for 4 hr, postfixed in 1%
osmium tetroxide, and embedded in an Epon-Araldite mixture. Semithin
sections (2 mm) were stained with toluidine blue. Thin sections were obtained
with anMT-X ultratome (RMC, Tucson, AZ, USA), stained with lead citrate, and299–310, March 7, 2012 ª2012 Elsevier Inc. 307
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Brain 2-AG Signaling Controls Energy Metabolismexamined with a CM10 transmission electron microscope (Philips, Eindhoven,
The Netherlands).
Body Composition
Fat mass and lean mass were measured in freely moving mice using 1H
magnetic resonance spectroscopy (EchoMRI-100; Echomedical Systems,
Houston, TX, USA) and expressed as percentage of total body mass.
Measurements for each mouse were performed in triplicate, and the average
of three replicates was used for statistical purposes. In the diet-induced
obesity experiment, weights of individual organs and fat pads were measured
after dissection.
Blood Chemistry
Blood analyses were performed using plasma from 18-week-old mice, unless
indicated otherwise. Glucose and triglyceride levels were quantified in tripli-
cate using colorimetric assays (Cayman Chemical, Ann Arbor, MI, USA).
Insulin and leptin levels were determined in duplicate by ELISA (Millipore,
Billerica, MA, USA). For glucose tolerance tests, 17- to 18-week-old mice
were food deprived for 4 hr, and glucose (2 mg/g) was administered by intra-
peritoneal injection. Blood was taken from the tail at 0, 30, 60, and 150 min
after injection, and glucose levels were measured in serum.
Feeding Behavior
Food intake was recorded in free-feedingmice using an automatedmonitoring
system (Scipro, New York, NY, USA) as described (Gaetani et al., 2003). Meal
analysis was performed adopting aminimum interresponse interval separating
two meals of 10 min. The following feeding parameters were analyzed: total
food intake during 24 hr (g/kg), feeding latency (min), meal size (g/kg), eating
rate ([g/kg]/min), and meal frequency (meals/hr).
Diet-Induced Obesity
Wild-type and MGL-Tg mice (20-week-old) were single housed (22C on
a 12 hr light/dark cycle) and kept for 10 weeks on a high-fat diet (60 kcal %
fat, Research Diets, Inc., New Brunswick, NJ, USA) with free access to water.
At the end of the experiment, animals were food deprived for 4 hr and killed.
Metabolic Chamber Recordings
Adult mice were acclimated to metabolic chambers (TSE Systems, Germany)
for 3 days before beginning the recordings. Energy expenditure, respiratory
exchange ratio, food intake, water intake, and locomotor activity (in x and
z axis) were measured simultaneously over a 24 hr period for two consecutive
days. VO2, VCO2, and energy expenditure were calculated following manufac-
turer’s guidelines (PhenoMaster Software, TSE Systems).
Motor Activity
The TSE Indirect Calorimetry Systemwas customized to include amultidimen-
sional light beam and light sensor system. The parallel beams were set up
close enough so that no mouse could be in the calorimeter cage without at
least one light beam being broken by its body. The motor activity-monitoring
software of this system was programmed to interpret breaking of consecutive
beams of the lower level of the beam grid to indicate ambulatory movement.
Recorded breaks of light beams within a second beam grid located in the
upper half of the home cage would be interpreted as rearing behavior, which
often correlates with feeding from hanging feeders or climbing activities.
Finally, rapid consecutive breaks and reconnection of the same light beams
were interpreted as stationary motor activity or fidgeting. The recordings of
such events were used to indicate shivering or fidgeting.
Temperature Measurements
Adult mice were food restricted overnight and anesthetized by intraperitoneal
injection of ketamine/xylazine. The mice were placed on a heating pad kept at
30C while core temperature was monitored using a rectal thermometer. After
20 min, the b3-adrenergic agonist CL-316243 (0.1 mg/kg, dissolved in saline)
(Tocris Bioscience, Ellisville, MO, USA) was administered by intraperitoneal
injection. Body temperature was recorded every min for 40 min. JZL184
(16 mg/kg, dissolved in 80% polyethylene glycol 200, 20% Tween-80)
(Cayman Chemical) was administered 6 hr before CL-316243, and rimonabant
(10 mg/kg, dissolved in 5% polyethylene glycol 200, 5% Tween-80 in saline)308 Cell Metabolism 15, 299–310, March 7, 2012 ª2012 Elsevier Inc.(RTI International, Research Triangle Park, NC, USA) was administered
15 min before JZL184.
Mitochondrial Activity
Interscapular BAT was isolated after 6 hr from intraperitoneal injection of
CL-316243 (0.1 mg/kg) or saline and homogenized in 2 ml of ice-cold buffer
containing MOPS (10 mM [pH 7.2]), mannitol (225 mM), sucrose (75 mM),
EGTA (1 mM), and 0.5% BSA. Homogenates were centrifuged at 600 3 g
for 10 min at 4C, and supernatants centrifuged again at 7,000 3 g for
10 min at 4C. Mitochondria-enriched pellets were suspended in a hypotonic
medium and freeze thawed three times. NADH-cytochrome c oxidoreductase
activity by Complex I and III was determined in an assay buffer containing
Tris-HCl (50 mM [pH 8.0]), BSA (5 mg/ml), oxidized cytochrome c (40 mM),
and potassium cyanide (0.24 mM). Reactions were initiated by addition of
NADH (0.8mM), and absorbance at 550 nmwasmeasured 3min later to quan-
tify cytochrome c reduction (Dı´az et al., 2009).
In Situ Hybridization
We prepared riboprobes ([35S]-cRNA) for Cartpt (coding region 1–390 of
mouse CART) using RNA polymerase (Roche, Indianapolis, IN, USA) in the
presence of [35S]-UTP. Coronal brain sections (20 mm thickness) were cut on
a cryostat (Microm-Thermo Scientific, Germany) and hybridized at 60C for
16 hr in buffer containing [35S]-cRNA (753 106 dpm/ml), 10% dextran sulfate,
50% formamide, 13 Denhardt’s solution, 100 mg/ml denatured salmon sperm
DNA, 0.15 mg/ml tRNA, and 40 mM dithiothreitol. After hybridization, the
sections were washed in gradient SSC solutions (43 SSC, 23 SSC,
13 SSC, and 0.13 SSC) and exposed to Kodak Biomax film (Sigma-Aldrich)
for 72 hr. The specificity of the hybridization signal was ascertained by hybrid-
ization of the same sections labeled with sense probes.
Statistical Analyses
Results are expressed as means ± SEM. Significance was determined using
two-tailed Student’s t test or two-way analysis of variance (ANOVA) with Bon-
ferroni post test, as appropriate, and differences were considered significant
if p < 0.05. Analyses were conducted using GraphPad Prism (GraphPad
Software, San Diego, CA, USA).
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